Abstract
Envonalkib (TQ-B3139, Env) is a novel small molecule ALK/ROS1/c-Met inhibitor. Here, we presented the primary analysis results of a phase III trial, aiming to evaluate the efficacy and safety of Env versus crizotinib (Cri) in advanced ALK-positive NSCLC patients (pts) who had not received a prior ALK inhibitor.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
